Biblio

Author Title Type [ Year(Desc)]
Filters: Author is Benner, Axel  [Clear All Filters]
2024
Appelbaum JS, Wei AH, Mandrekar SJ, Tiong IS, Chua CChyn, Teh T-C, Fong CYew, Ting SB, Weber D, Benner A, et al. Clinical evaluation of complete remission (CR) with partial hematologic recovery (CRh) in acute myeloid leukemia: a report of 7235 patients from seven cohorts. Leukemia. 2024.
Salwender H, Weinhold N, Benner A, Miah K, Merz M, Haenel M, Jehn C, Mai E, Menis E, Blau I, et al. Cytomegalovirus immunoglobulin serology prevalence in patients with newly diagnosed multiple myeloma treated within the GMMG-MM5 phase III trial. Hematology. 2024;29(1):2320006.
Mai EK, Goldschmid H, Miah K, Bertsch U, Besemer B, Hänel M, Krzykalla J, Fenk R, Schlenzka J, Munder M, et al. Elotuzumab, lenalidomide, bortezomib, dexamethasone, and autologous haematopoietic stem-cell transplantation for newly diagnosed multiple myeloma (GMMG-HD6): results from a randomised, phase 3 trial. Lancet Haematol. 2024;11(2):e101-e113.
Penack O, Luft T, Peczynski C, Benner A, Sica S, Arat M, Itälä-Remes M, Corral LLopez, Schaap NPM, Karas M, et al. Endothelial Activation and Stress Index (EASIX) to predict mortality after allogeneic stem cell transplantation: a prospective study. J Immunother Cancer. 2024;12(1).
Sala E, Neagoie AM, Lewerenz J, Saadati M, Benner A, Gantner A, Wais V, Döhner H, Bunjes D. Neurological complications of the central nervous system after allogeneic stem cell transplantation: the role of TA-TMA as a potential underreported cause. Transplant Cell Ther. 2024.